2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Antibody-Based Cancer Therapeutics
Antibody-based cancer therapeutics represent a promising frontier in cancer research, leveraging the body's own immune system to target and destroy cancer cells with remarkable precision. These therapies utilize monoclonal antibodies engineered to recognize specific proteins expressed on cancer cells, enabling targeted delivery of potent anti-cancer agents or triggering immune responses against tumors. By sparing healthy cells and minimizing side effects, antibody-based therapies offer a more targeted and personalized approach to cancer treatment. Key examples include immune checkpoint inhibitors like pembrolizumab and rituximab for certain lymphomas. Ongoing research continues to refine these therapies, exploring novel targets and combination strategies to enhance efficacy and broaden applicability across different cancer types, paving the way for more effective and less toxic treatments in the fight against cancer.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China